Published 2024-03-01
“…Shan-Shan Hong,1,* Yang Li,2,* Yu-Yi Lin,3 San-Gang Wu,4 Li-Ying Chen,1 Juan Zhou5 1Department of Obstetrics and Gynecology, Quanzhou Women’s and Children’s Hospital, Quanzhou, 362000, People’s Republic of China; 2School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, People’s Republic of China; 3Department of Radiation Oncology, the Second Affiliated Hospital of Xiamen Medical College, Xiamen, 361021, People’s Republic of China; 4Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, the First Affiliated Hospital of
Xiamen University, School of Medicine,
Xiamen University, Xiamen, 361003, People’s Republic of China; 5Department of Obstetrics and Gynecology, the First Affiliated Hospital of
Xiamen University, School of Medicine,
Xiamen University, Xiamen, 361003, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li-Ying Chen, Department of Obstetrics and Gynecology, Quanzhou Women’s and Children’s Hospital, Quanzhou, 362000, People’s Republic of China, Email aziliying@163.com Juan Zhou, Department of Obstetrics and Gynecology, the First Affiliated Hospital of
Xiamen University, School of Medicine,
Xiamen University, Xiamen, 361003, People’s Republic of China, Email zhoujuan@xmu.edu.cnPurpose: To determine the disparities in survival outcomes between stage IIB-IVA cervical squamous cell carcinoma (SCC) and adenocarcinoma (AC) treated with chemoradiotherapy.Methods: Patients diagnosed between 2004 and 2015 were retrospectively included from the Surveillance, Epidemiology, and End Results databases. …”
Get full text
Article